SCHEDULE: Invesco Ltd. Reports 6.1% Stake in Ligand Pharmaceuticals

Invesco Ltd. has disclosed beneficial ownership of 6.1% of Ligand Pharmaceuticals Inc.'s common stock as of June 30, 2026.

Summary

• Invesco Ltd. has filed a Schedule 13G, indicating it beneficially owns 1,218,846 shares of Ligand Pharmaceuticals Inc. common stock.
• This ownership represents 6.1% of the class of securities.
• The filing is made by Invesco Ltd. as a parent holding company for its investment advisers.
• The shares are held by clients of Invesco Ltd., with Invesco Ltd. having sole voting power for 1,199,033 shares and sole dispositive power for 1,218,846 shares.
• The date of the event requiring the filing was June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without significant new information or strategic shifts.

Positives

• Invesco Ltd. maintains a significant ownership stake, suggesting continued confidence in Ligand Pharmaceuticals.
• The filing clearly outlines Invesco's voting and dispositive power, providing transparency to the market.

Negatives

• No new strategic information or financial performance data is provided in this filing.

Risks

• The filing does not contain specific risk factors related to Ligand Pharmaceuticals' business operations.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Invesco Ltd. is a standard disclosure for institutional investors crossing certain ownership thresholds. It reflects ongoing investment activity within the biotechnology and pharmaceutical sectors, where significant stakes are common.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's holdings.
• Management: Awareness of Invesco's substantial stake may influence strategic decisions.
• Potential Investors: The filing provides data points for assessing institutional interest in Ligand Pharmaceuticals.

Next Steps

• Invesco Ltd. will continue to hold its investment in Ligand Pharmaceuticals Inc. as per its investment strategy.
• Further filings will be made if ownership levels change significantly.

Key Dates

Keywords

Ligand Pharmaceuticals, Invesco Ltd., Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Securities Exchange Act